Proton Pump Inhibitors (PPI): Pharmacology Made Easy & Clinically Relevant
The PPIs are antacids used in conditions like gastritis, peptic ulcer disease, H. pylori, & GERD. Their value lies in understanding how and why they differ from other antacids. Don't just memorize. Learn to understand.
To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why with Dr. Busti pharmacology review, Dr. Busti dives into the antacids, proton pump inhibitors (PPIs)—one of the most transformative and widely used drug classes in modern medicine. These agents, including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole, fundamentally changed the treatment of GERD, peptic ulcer disease, erosive esophagitis, and H. pylori infection by overcoming the limitations of H₂ receptor antagonists, especially tolerance and incomplete acid suppression.
This episode connects the why behind their clinical use:
- How irreversible inhibition of the H⁺/K⁺-ATPase achieves durable acid control
- Why pH >4 (healing) and >6 (bleeding control) are clinical targets
- How genetic polymorphisms (CYP2C19) and drug interactions (e.g., clopidogrel) influence outcomes
- What side effects matter most long-term — from hypomagnesemia and B₁₂ deficiency to infection risks and bone effects
Whether in the ICU (IV pantoprazole/esomeprazole) or outpatient care, this review helps you master when, why, and how to use PPIs effectively.
Chapter Table of Contents
00:00 Introduction to Proton Pump Inhibitors (PPIs)
00:48 Why PPIs Matter: Clinical Relevance & Limitations of H2 Blockers
03:54 PPI Therapeutic Indications: GERD, Ulcer Disease, H. pylori Regimens
14:23 Safety Profile & Adverse Effects: Hypomagnesemia, B12, Fractures, C. diff
15:42 PPI Mechanism of Action: Irreversible H+/K+ ATPase Inhibition
19:12 PPI Dosing Strategies: Timing, Administration, and Clinical Pearls
24:06 Pharmacokinetics: Bioavailability, Activation, Duration, Acid-Labile Features
30:57 Drug Interactions: CYP2C19, Clopidogrel, and Clinical Impact
#protonpumpinhibitors #pharmacology #gipharmacology #medicaleducation
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
